美英两国将取消毒品关税,提高国民保健服务的支付率,并改善市场准入。 U.S. and UK to eliminate drug tariffs, boost NHS payments, and improve market access.

美国和英国将取消对药品、医疗技术和原料的关税,联合王国同意将新药品的国民保健制度付款提高25%,并修订成本效益评估门槛。 The U.S. and U.K. are set to eliminate tariffs on pharmaceuticals, medical technology, and ingredients, with the UK agreeing to raise NHS payments for new medicines by 25% and revise its cost-effectiveness evaluation threshold. 该协议预期在白宫达成,目的是增加对英国制药部门的投资,解决对AstraZeneca和Merck等公司项目停滞的担忧,并与其他富裕国家统一定价。 The deal, expected at the White House, aims to boost investment in the UK’s pharmaceutical sector, address concerns over stalled projects by companies like AstraZeneca and Merck, and align pricing with other wealthy nations. 联合王国还将减少对品牌药品的回扣,并增加药品支出,而美国对联合王国的药品出口将获得免关税准入。 The UK will also reduce rebates on branded drugs and increase spending on medicines, while U.S. drug exports to the UK will gain tariff-free access. 该协定是经过数月的谈判和美国施加压力以改善市场准入和价格公平之后达成的。 The agreement follows months of negotiations and pressure from the U.S. to improve market access and pricing fairness.